Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: M.S.H who wrote (1157)	6/5/1998 12:03:00 PM
From: Jeffrey L. Henken	Read Replies (3) \| Respond to of 2887

Please call Steve Rash. They have already used some of the money from that $5 million equity line of credit. If they did not have the money the company would not be able to start phase II trials of the OmniCath. That is exactly what will be happening very soon. Whatever conditions were necessary in order to borrow must have been met because the company is, like it or not, borrowing from that equity line of credit. One other issue you raised concerning press releases. American BioMed often issues a press release containing multiple newsworthy items simply to hold done the cost of several press releases. Thanks for your opinion. Regards, Jeff